Healthcare / BiotechnologyASX
$0.61
+0.01 (+1.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $4.1M · quality 78.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$29M
P/E
10.2x
↓EV/EBITDA
0.7x
↓ROE
24.0%
↑Gross Margin
74.3%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+64.5%
FCF CAGR
+29.4%
FCF margin
6.1%
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $66.9M · net income $6.7M · FCF $4.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $66.9M | $66.9M | $66.4M | $37.1M | $15.0M |
| Net Income | $6.7M | $6.7M | $7.0M | $3.6M | $1.3M |
| EBITDA | $11.1M | $11.1M | $10.4M | $5.1M | $1.9M |
| EPS | 0.15 | 0.15 | 0.16 | 0.09 | 0.03 |
| Gross Margin | 74.3% | 74.3% | 76.7% | 76.8% | 50.0% |
| Operating Margin | 14.8% | 14.8% | 14.6% | 12.4% | 10.9% |
| Net Margin | 10.1% | 10.1% | 10.5% | 9.8% | 8.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 |
| Current Ratio | 6.57 | 6.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.1M | $4.1M | $5.7M | $3.9M | $1.9M |
| Returns | |||||
| ROE | 24.0% | 24.0% | 32.7% | 24.9% | 11.5% |
| Valuation | |||||
| P/E | 10.17 | 10.17 | 10.42 | 6.00 | 9.39 |
| EV/EBITDA | 0.69 | 0.69 | 5.18 | 1.65 | 1.03 |
| P/B | 1.00 | 1.00 | 3.40 | 1.49 | 1.08 |
| Growth & Yield | |||||
| Revenue Growth | 0.6% | 0.6% | 78.9% | 147.3% | — |
| EPS Growth | -9.9% | -9.9% | 90.2% | 175.1% | — |
| Dividend Yield | 6.7% | 6.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-28.1%
EPS terminal req.
$0.05
Spread vs growth
18.2%
5Y implied EPS CAGR
-14.8%
EPS terminal req.
$0.07
Spread vs growth
4.9%
10Y implied EPS CAGR
-3.2%
EPS terminal req.
$0.11
Spread vs growth
-6.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-53.3%
Start / end P/E
9.4x → 4.2x
EPS bridge
0.16 → 0.15
Residual
+5.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.